18 results on '"Bo, Qingyan"'
Search Results
2. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial
3. Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and naive chronic hepatitis B patients: 48-week treatment and post-treatment follow-up
4. Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients
5. Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers
6. Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B
7. How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti–Hepatitis B Virus Drug
8. What drives the dynamics of HBV RNA during treatment?
9. A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants
10. Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers.
11. Resistance monitoring data from treatment-naive chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator RO7049389 monotherapy
12. FRI-219-RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients
13. What drives the dynamics of HBV RNA during treatment?
14. Nationwide survey of specialist knowledge on current standard of care (Peg‐IFN/RBV) and barriers of care in chronic hepatitis C patients in China
15. Glucose abnormalities in Asian patients with chronic hepatitis C
16. Real-World Evidence for Nucleoside/Nucleotide Analogues in a 5-Year Multicentre Study of Antiviral-Naive Chronic Hepatitis B Patients in China: 52-Week Results
17. SAT395 - Resistance monitoring data from treatment-naive chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator RO7049389 monotherapy.
18. Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.